PCSK9 and metabolic syndrome: Hypothyroidism can also lead to dyslipidemia by influencing regulatory factors such as sterol regulatory element binding proteins (SREBPs), proprotein convertase subtilisin/kexin type 9 (PCSK9), and fibroblast growth factor 19/21 (FGF19/21), which were reported to be associated with lipid metabolism.